Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The Oncotype DX Breast Cancer Assay is validated to assess risk of distant recurrence and likelihood of chemotherapy (CT) benefit in estrogen receptor-positive ESBC in various populations. In Hong Kong, > 80% of breast cancers are early stage breast cancer (ESBC) and > 60% of these women receive CT. This prospective study measured changes in CT type and recommendations, as well as physician impression of assay impact in a homogenous Chinese population.
Methods: Consecutive patients with estrogen receptor-positive, T1-3 N0-1mi M0 ESBC were offered enrollment. After surgery, physicians discussed treatment options with patients, then ordered the assay, then reassessed treatment recommendation considering assay results. Changes in treatment recommendation, CT utilization, physician confidence, and physician rating of influence on their treatment recommendations were measured.
Results: A total of 146 evaluable patients received pre- and post-testing treatment recommendations. CT recommendations (including changes in intensity of CT) were changed for 34 of 146 patients (23.3%; 95% confidence interval, 16.7%-31.0%); change in intensity occurred in 7 of 146 (4.8%). There were 27 changes in treatment recommendations of adding or removing CT altogether (18.5% change; 95% confidence interval, 12.6%-25.8%). CT recommendations decreased from 52.1% to 37.7%, a net absolute reduction of 14.4% (P < .001; 27.6% net relative reduction). Pre-assay, 96% of physicians agreed/strongly agreed that they were confident in their treatment recommendation; post-assay, 90% of physicians agreed/strongly agreed with the same statement. Thirty percent of physicians agreed/strongly agreed that the test had influenced their recommendation, similar to the proportion of changed recommendations.
Conclusions: The Oncotype DX Assay appears to influence physician ESBC adjuvant treatment recommendations in Hong Kong.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clbc.2016.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Need Analysis of Clinician-Oriented Integrated Precision Oncology Decision Support Tools: Qualitative Descriptive Study.
JMIR Hum Factors
September 2025
College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, China.
Background: The rapid advancement of next-generation sequencing has significantly expanded the landscape of precision medicine. However, health care professionals face increasing challenges in keeping pace with the growing body of oncological knowledge and integrating it effectively into clinical workflows. Precision oncology decision support (PODS) tools aim to assist clinicians in navigating this complexity, yet their current functionalities only partially address clinical needs.
View Article and Find Full Text PDFPay-It-Forward 23-Valent Pneumococcal Polysaccharide Vaccination Among Older Adults: Protocol for a Randomized Controlled Trial.
JMIR Res Protoc
September 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health & Life Science Institute, Guangxi Medical University, Nanning, China.
Background: The 23-valent pneumococcal polysaccharide vaccine reduces the risk of pneumonia among adults by 38% to 46%. However, only a few older adults in resource-limited areas of China have received the pneumococcal vaccination. Pay-it-forward is a social innovation that offers participants free or subsidized health services and a community-engaged message, with an opportunity to donate to support subsequent recipients.
View Article and Find Full Text PDFQuality indicator survey of clinical practice guidelines for esophagogastric junction cancer 2023.
Dis Esophagus
October 2025
Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Clinical practice guidelines for esophagogastric junction cancer (EGJ GLs) were published in 2023. In order to evaluate how EGJ GLs have been adopted into clinical practice worldwide and to identify any outstanding clinical questions to be addressed in the next edition, this survey was conducted. An electronic questionnaire was developed.
View Article and Find Full Text PDFUltrasonic extraction, Structural Characterization, and Immunoactivity of Polysaccharides From Syzygium jambos (L.) Alston.
Chem Biodivers
September 2025
College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
This research emphasized the extraction and separation of polysaccharides derived from Syzygium jambos (L.) Alston (PSJAP-5), as well as analyses of their structural characteristics and immunomodulatory activities. This study initially employed response surface methodology to determine the extraction conditions of polysaccharides.
View Article and Find Full Text PDF[Transitioning to adult oncology for adolescents and young adults (AYAs): The experience of an AYA unit].
Med Sci (Paris)
September 2025
Département de cancérologie de l'enfant et l'adolescent (DCEA), Gustave Roussy cancer campus, Villejuif, France - Équipe mobile SPIAJA, équipe spécifique de prise en charge interdisciplinaire des adolescents et jeunes adultes, Gustave Roussy cancer campus, Villejuif, France.
Supporting the transition from pediatric to adult oncology presents challenges for all stakeholders, including adolescent and young adult (AYA) patients, their parents, pediatric oncologists, and medical oncologists. In this article, we describe the different stages of this transition and the transfer of care, the obstacles to the transition, and potential solutions. We discuss the contribution of AYA care in oncology through collaborations between pediatric and medical oncologists, and the importance of multidisciplinary support for patient empowerment.
View Article and Find Full Text PDF